Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: April 2013

9 - Enabling Drug Discovery Technologies for Regenerative Pharmacology

from Section II - Enabling Technologies for Regenerative Pharmacology


1. LesneyM.Patents and potions: entering pharmaceutical industry.” The Pharmaceutical Century: Ten Decades of drug Discovery Supplement to the American Chemical Society; 2000, p. 18–31. American Chemical Society Publications, Washington DC.
2. DrewsJ.Drug discovery: a historical perspective.” Science. 2000; 287, 1960–1964.
3. DrewsJ. “In quest of tomorrow's medicines.” New York: Springer 1998.
4. MayrLM, FuerstP. “The future of high throughput screening.” J Biomol Screen. 2008; 13, 443–448.
5. GarnierJ.Rebuilding the R&D engine in big pharma.” Harvard Bus Rev. 2008; 86, 68–76.
6. MacarronR, BanksMN, Bojanic, D, Burns, DJ, CirovicDA, GaryantesT, GreenDVS, HertzbergRP, JanzenWP, PaslayJW, SchopferU, SittampalamGS. “Impact of high throughput screening in biomedical research.” Nat Rev Drug Disc. 2011; 10, 188–195.
7. AnderssonK-E, ChristGJ. Regenerative pharmacology: the future is now.” Mol Interv. 2007; 7, 79–86.
8. NirmalanandhanVS, SittampalamGS.Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges.” J Biomol Screen. 2009; 14, 755–768.
9. Furth, ME, ChristGJ. “Regenerative pharmacology for diabetes mellitus.” Mol Interv. 2009; 9, 171–174.
10.“2020: A New Vision – A Future for Regenerative Medicine.” Washington, DC: US Department of Health and Human Services.
11. NelsonTJ, BehfarA, TerzicA.Stem cells: biologics for regeneration.” Clin Pharm Ther. 2008; 84, 620–623.
12. EggertUS, Superti-FurgaG. “Drugs in action.” Nat Chem Biol.2008; 4(1), 7–11.
13. Royal Society of Chemistry. Advances in Chemical Sciences. “Chemical Biology – A Vital Partnership for Progress.” 2006.
14. DrewsJ. “Genomic sciences and the medicine of tomorrow.”Nat Biotechnol. 1996; 14, 1516–1518.
15. DuFortCC, PaszekMJ, WeaverVM. “Balancing forces: architectural control of mechanotransduction.” Nat Rev Mol Cell Biol. 2011; 12, 308–319.
16. CrooksSL, CharelsLJ. “Overview of combinatorial chemistry.” Curr Protoc Pharmacol. 2000; 9(3), 1–16.
17. MaltaisR, TremblayMR, CiobanuLC, PoirierD. “Steroids and combinatorial chemistry.” J Comb Chem. 2004; 6(4), 443–456.
18. DreckerS. “Necessity is the mother of invention.” BioTEK Technical Bulletin. 2004. GIT Labor-Fachzeitschrift 12/2004, S. 1120-1121, GIT VERLAG GmbH & Co. KG, Darmstadt,
19. IngleseI, JohnsonRL, SimeonovA, XiaM, ZhengW, AustinCP, AuldDA.High-throughput screening assays for the identification of chemical probes.” Nat Chem Biol. 2007; 3(8), 466–479.
20. Traulau-StewartCJ, WyattCA, KleynDE, AlexA. “Drug discovery: new models for industry-academic partnerships.” Drug Discov Today. 2009; 14 (1/2), 95–101.
21. TyersM, MannM. “From genomics to proteomics.” Nature. 2003; 422, 193–197.
22. SimonCG, Lin-GibsonS.Combinatorial high throughput screening of biomaterials.” Adv Mater. 2011; 23(3), 369–387.
23. YlliperttulaM, Chung, BG, NavaladiA, ManbachiA, UrttiA. “High-throughput screening of cell responses to biomaterials.” Eur J Pharm Sci. 2008; 35, 151–160.
24. DaunertS, BarrettG, FelicianoJS, ShettyR, ShresthS, Smith-SpenceW.Genetically engineered whole cell sensing systems: coupling biological recognition with reporter genes.” Chem Rev. 2000; 100, 2705–2738.
25. WoodKV: “The chemistry of bioluminescent reporter assays.” Promega News. 1998, No.65; p. 14.
26. PerezFA, MuleroV, and CayuelaML: “Application of dual-luciferase reporter assay to the analysis of promoter activity in zebra fish embryos.” BMC Biotec. 2008; 8:81; pp-1–8.
27. Promega Dual Luciferase Reporter System Technical Manual. Revised August 2006: Part No. TM046, Promega Corp. Madison, WI, USA.
28. NakjamaY, KimuraT, SugataK, EnomotoT, AskawaA, IkedaM, OhmiyaY. “Multicolor luciferase assay system: one step monitoring of multiple gene expressions with a single substrate.” BioTechniques. 2005; 38, 891–894.
29. HidaN, AwaisM, TakeuchiM, UenoN, TashiroM, TakagiC, SinghT, HayashiM, OhmiyaY, OzawaT.High-sensitivity real-time imaging of dual protein-protein interactions in living subjects using multicolor luciferases.”PLoS One. 2009; 4(6), e5868.
30. HallisTM, KoppAL, GibsonJ, LebakkenCS, HancockM, Van Den Heuvel-KramerK, Turek-EtienneT. “An improved b-lactamase reporter assay: multiplexing with cytotoxicity readout for enhanced accuracy for hit detection.” J Biomol Screen. 2007; 12(5), 635–644.
31. SteinDC, CarrizosaE, DunhamS. “Use of nfsB, encoding nitroreductase, as a reporter gene to determine the mutational spectrum of spontaneous mutations in Neisseria gonorrhoeae.” BMC Microbiol. 2009; 9, 239.
32. AuldDS, ZhangYQ, VeithH, Jadhav, A, YasgarA, SimeonovA, ZhengW, MartinezED, WestwickJK, AustinCP, IngleseJ. “Fluorescent protein bases cellular assays analyzed by laser scanning microplate cytometry in 1536-well format.” Methods in Enzymo. 2006; 414, 566–589.
33. PrasherDC, EckenrodeVK, WardWW, PrendergastFG, CormierMJ.Primary structure of the Aequorea victoria green-fluorescent protein.” Gene. 1992; 111, 229–233.
34. ChalfieM G, EuskirchenG, WardWW, PrasherDC. “Green fluorescent protein as a marker for gene expression.” Science. 1994; 263, 802–805
35. KremersG-J, GilbertSG, CranfillPJ, DavidsonMW, PistonDW. “Fluorescent proteins at a glance.” J Cell Sci. 2011; 124(2), 157–160.
36. ZanellaF, LorensJB, InkW. “High content screening: seeing is believing.” Trends Biotechnol. 2010; 28(5), 237–245.
37. ShuX, RoynatA, LinMZ, AguileraTA, Lev-RamV, SteibachPA, TsienRY. “Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome.” Science. 2009; 234, 804–807.
38. PistonDW, PattersonGH, Lippincott-SwartzJ, ClaxtonNS, DavidsonMW. “Introduction to fluorescent proteins.” 2010.
39. LukyanovKA, ChudakovDM, LukyanovS, and VerkhushaVV.Innovation: photoactivatable fluorescent proteins.” Nat Rev Mol Cell Biol. 2005; 6, 885–891.
40. AlbertsB, JohnsonA, LewisJ, RaffM, RobertsK, WalterP. Molecular Biology of the Cell, 5th edition. New York: Garland Science, Taylor & Francis; 2008.
41. GregoryKJ, SextonPM, ChristopoulosA. HickCA. 2010 second messenger assays for G protein-coupled receptors: cAMP, Ca2+, inositol phosphates, ERK1/2. In G Protein-Coupled Receptors: Essential Methods, edited by D.R. Poyner, M. Wheatley. Oxford, UK: Wiley-Blackwell.
42. SchroederKS, NeagleBD. “FLIPR: a new instrument for accurate, high throughout optical screening.” J Biomol Screen. 1996; 1(2), 75–80.
43. WhitakerKL, SullivanJP, GopalakrishnanM. “ Cell-based assays using Fluorometric Imaging Plate Reader (FLIPR).” Curr Protoc Pharmacol 2000; 9.2.1–9.2.23.
44. Summary of molecular probes fluorescent Ca2+ indicators. In The Molecular Probes® Handbook, 11th edition. 2011. Life Technologies, Grand Island, NY.
45.“FLIPR Assays to measure GPCR and ION Channel Targets” 2011.
46. TitusSA, BeachamD, ShahaneSA, SouthallN, XiaM, HuangR, HootenE, ZhaoY, ShouL, AustinCP, ZhengW. “A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.” Anal Biochem. 2009; 394(1), 30–38.
47. GollaR, SeethalaR. “A homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists.” J Biomol Screen. 2002; 7(6), 515–525.
48. ClaverieJM, NotredameC. Bioinformatics for Dummies. Wiley; Hoboken, NJ, 2003.
49. BaxevanisAD, OuelletteBFF. (eds.) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, third edition. Wiley, 2005. ISBN 0–471-47878–4.
50. CongreveM, MurrayCW, BlundellTM. “Structural biology and drug discovery.” Drug Discov Today. 2005; 10(13), 895–907.
51. DingS, SchultzPG. “A role for chemistry in stem cell biology.” Nat Biotech. 2004; 22(7), 833–840.
52. KorblingM, PrzepiorkaD, HuhYO, EngelH, van BesienK, GiraltS, AnderssonB, KleineHD, SeongD, DeisserothAB. “Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.” Blood. 1995; 85(6), 1659–1665.
53. TakahashiK, TanabeK, OhnukiM, Narita M, IchisakaT, TomodaK, YamanakaS. “Induction of pluripotent stem cells from adult human fibroblasts by defined factors.” Cell. 2007; 131(5), 861–872.
54. SoldnerF, HockemeyerD, BeardC, GaoQ, BellGW, CookEG, HargusG, BlakA, CooperO, MitalipovaM, IsacsonO, HJaenischR.Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.” Cell 2009; 136(5), 964–977.
55. Kim, S-K. “Converting human skin cells to neurons: a new tool to study and treat brain disorders?Cell Stem Cell. 2011; 9, 179–180.
56. IedaM, FuJ-D, Delgado-OlguinP, VedanthamV, HyashiY, BruneauB, SrivastavaD. “Direct reprogramming if fibroblasts into functional cardiomyocytes by defined factors.” Cell. 2010; 142, 375–386.
57. ChristGJ, ChenAF.The grand challenge for integrative and regenerative pharmacology.” Front Pharmacol. 2011; 2 (5), 1–2.
58. ChristGJ, FurthME.Regenerative pharmacology for diabetes mellitus.” Mol Interven. 2009; 9(4), 171–174.
59. MozettaC, MinettiG, PuriPL. “Regenerative pharmacology in the treatment of genetic disorders: the paradigm for muscular dystrophy.” Int J Biochem Cell Biol. 2009; 41, 701–710.
60. BegleyS, CarmichaelM. “Desperately seeking cures: how the road from promising scientific breakthrough to real-world remedy has become all but a dead end.” Newsweek. 2010; May 31, pp. 38–42.
61. BorelJF. “History of the discovery of cyclosporine and of its early pharmacological development.” Wien Klin Wochenschr. 2002; 114(12), 433–437.
62. LeeJA, UhlickMT, MoxhamCM, TomandlD, SallDJ. “Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.” J Med Chem. 2012; 55, 4527–4538.
63. IngleseJ, ShamuCE, GuyRK.Reporting data from high-throughput screening of small-molecule libraries.” Nat Chem Biol. 2007; 8(3), 438–441.